Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors.

e14620 Background: LDTs have been shown to improve time to tumor progression and morbidity in metastatic neuroendocrine tumors (mNETs). CgA and PcSt are being used to predict and evaluate response to LDTs. Methods: Medical records of 42 mNET patients (pts) with hepatic metastases treated with either bland hepatic artery embolization (HAE), chemoembolization (HACE), or hepatic radioembolization (HRE) at the University of Iowa from 2001 to 2011 were analyzed. Time to progression (TTP) and overall survival (OS) were calculated using Kaplan-Meier analysis. PcSt and CgA were compared using a standardized mean Results: The tumors were located in the small bowel in 21 pts (50%), pancreas in 8 (19%), lung in 2 (5%), and other locations in 11 pts (26%). 13 pts had HAE, 17 had HACE and 12 had HRE. 20 pts had a second procedure with 6 receiving HRE, 9 HAE and 5 HACE. There was no significant difference in initial radiographic response among the three treatments (p = 0.082). TTP was similar between HRE (15.1 months) ...